Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | NEJM
SOLO-1 Phase 3 Trial – Efficacy of LYNPARZA® (olaparib) for BRCAm Advanced Ovarian Cancer
Cancers | Free Full-Text | CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis Data
Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer - ScienceDirect
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy | British Journal of Cancer
Multimodal Treatment of Primary Advanced Ovarian Cancer | Anticancer Research
392 Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: subgroup analysis by risk in the phase III solo1 study | International Journal of Gynecologic Cancer
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial - Annals of Oncology
SOLO-1 Phase 3 Trial – Efficacy of LYNPARZA® (olaparib) for BRCAm Advanced Ovarian Cancer
SGO on Twitter: "Improved overall survival with olaparib maintenance was clear - even when pts in the placebo group were treated with #PARPi in a later line - important information for sequencing
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology
Survival Rates in Stage IV Melanoma Patients Treated Immunotherapy and Radiation Differ According to Age and Radiation Treatment
Final Overall Survival Analysis From SOLO2 in Ovarian Cancer - The ASCO Post
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology
Real-World Treatment Patterns, Survival, and Costs for Ovarian Cancer in Canada: A Retrospective Cohort Study Using Provincial Administrative Data | Published in Journal of Health Economics and Outcomes Research
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology
SOLO-1 Phase III trial demonstrates Lynparza maintenance therapy cut risk of disease progression or death by 70% in patients with newly-diagnosed, advanced BRCA-mutated ovarian cancer
Real-World Use and Outcomes of Olaparib: a Population-Based Cohort Study | SpringerLink
Olaparib maintenance for first-line treatment of ovarian cancer: will SOLO1 reset the standard of care? | Future Oncology
Nachwuchsförderung der SAKK – Rosenfluh.ch
SOLO-1 Phase 3 Trial – Efficacy of LYNPARZA® (olaparib) for BRCAm Advanced Ovarian Cancer
Lynparza Delays Progression & Significantly Prolongs Survival in Ovarian Cancer - CancerConnect
SOLO-1: Seven-Year Follow-up Data Confirm Maintenance Olaparib Benefit in Ovarian Cancer
5-year follow-up data from the SOLO-1 trial with analysis of the information up to March 5, 2020 were highlighted at ESMO 2020 - Onco Americas
Cancers | Free Full-Text | Improved Prognostic Stratification Using Circulating Tumor Cell Clusters in Patients with Metastatic Castration-Resistant Prostate Cancer
